| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L Wang, C Fang, A Zhang, J Du, L Yu, J Ma, G Feng, Q Xing, L H. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. Journal of psychopharmacology (Oxford, England). vol 22. issue 8. 2009-01-13. PMID:18308786. |
we investigated the relationship between the c825t polymorphism of gbn3 (rs5443) and the -1019 c/g polymorphism of 5-ht(1)a (rs6295) and response to risperidone treatment. |
2009-01-13 |
2023-08-12 |
Not clear |
| L Wang, C Fang, A Zhang, J Du, L Yu, J Ma, G Feng, Q Xing, L H. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. Journal of psychopharmacology (Oxford, England). vol 22. issue 8. 2009-01-13. PMID:18308786. |
the results suggest that the -1019 c/g polymorphism (rs6295) in the 5-ht(1)a gene may be a useful predictor of reduction in negative symptoms in schizophrenic patients treated with risperidone. |
2009-01-13 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, Tomiki Sumiyosh. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behavioural brain research. vol 195. issue 1. 2009-01-12. PMID:18707769. |
aripiprazole, clozapine, olanzapine, perospirone, quetiapine risperidone, and ziprasidone are examples of atypical antipsychotic drugs which are either direct or indirect 5-ht(1a) agonists which have been shown to improve cognitive function in patients with schizophrenia. |
2009-01-12 |
2023-08-12 |
Not clear |
| Martina Rojnic Kuzman, Vesna Medved, Nada Bozina, Ljubomir Hotujac, Ivica Sain, Hrvoje Bilusi. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry research. vol 160. issue 3. 2008-11-26. PMID:18718676. |
we investigated the relationships between functional genetic variants of the 5-ht(2c) receptor and multidrug-resistant protein (mdr1), coding for p-glycoprotein, and second generation antipsychotic (sda)-induced weight gain among 108 female schizophrenic patients treated with olanzapine or risperidone for up to 4 months. |
2008-11-26 |
2023-08-12 |
Not clear |
| Giuseppe Maina, Enrico Pessina, Umberto Albert, Filippo Bogett. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 18. issue 5. 2008-07-02. PMID:18280710. |
8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. |
2008-07-02 |
2023-08-12 |
human |
| Barbara O Rothbaum, Therese K Killeen, Jonathan R T Davidson, Kathleen T Brady, Kathryn M Connor, Mary H Heeki. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. The Journal of clinical psychiatry. vol 69. issue 4. 2008-06-16. PMID:18278987. |
placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. |
2008-06-16 |
2023-08-12 |
Not clear |
| Lesley J Scott, Sohita Dhillo. Spotlight on risperidone in irritability associated with autistic disorder in children and adolescents. CNS drugs. vol 22. issue 3. 2008-05-19. PMID:18278980. |
risperidone (risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine d(2) and serotonin 5-ht(2a) receptor antagonism. |
2008-05-19 |
2023-08-12 |
Not clear |
| Byungsu Kim, Eui Yul Choi, Chang Yoon Kim, Kyuyung Song, Yeon Ho Jo. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Human psychopharmacology. vol 23. issue 1. 2008-03-18. PMID:17924589. |
this study seeks to replicate previous results indicating that t102c in the serotonin 2a receptor (htr2a) and ser9gly in the dopamine d3 receptor (drd3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting. |
2008-03-18 |
2023-08-12 |
Not clear |
| Eliyahu Dremencov, Mostafa El Mansari, Pierre Blie. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology. vol 194. issue 1. 2008-01-23. PMID:17530476. |
distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. |
2008-01-23 |
2023-08-12 |
rat |
| Frans H L Awouters, Paul J Lew. Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen. Arzneimittel-Forschung. vol 57. issue 10. 2008-01-22. PMID:18074755. |
this research ultimately led to the discovery of risperidone (cas 106266-06-2) and paliperidone (cas 144598-75-4), compounds with inbuilt dopamine and serotonin antagonism. |
2008-01-22 |
2023-08-12 |
Not clear |
| Ruchika Chakrabarty, Jyoti Rao, Aparna Anand, Abhijeet Deb Roy, Raja Roy, G Shankar, P R Dua, Anil K Saxen. Rational design, synthesis and evaluation of (6aR( *),11bS( *))-1-(4-fluorophenyl)-4-{7-[4-(4-fluorophenyl)-4-oxobutyl]1,2,3,4,6,6a,7,11b,12,12a(RS)-decahydropyrazino[2',1':6,1]pyrido[3,4-b]indol-2-yl}-butan-1-one as a potential neuroleptic agent. Bioorganic & medicinal chemistry. vol 15. issue 23. 2008-01-11. PMID:17869521. |
this molecule has shown d(1), d(2) and 5-ht(2a) receptor blocking activity where the ratio pk(i) (5-ht(2a)) to pk(i) (d(2)) is 1.42 better than risperidone (1.15). |
2008-01-11 |
2023-08-12 |
Not clear |
| Lesley J Scott, Sohita Dhillo. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatric drugs. vol 9. issue 5. 2008-01-11. PMID:17927305. |
risperidone (risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine d(2) and serotonin (5-ht [5-hydroxytryptamine])(2a) receptor antagonism. |
2008-01-11 |
2023-08-12 |
Not clear |
| Mark Slifstein, Lawrence S Kegeles, Robyn Gonzales, William G Frankle, Xiaoyan Xu, Marc Laruelle, Anissa Abi-Dargha. [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 27. issue 10. 2007-10-17. PMID:17311076. |
in this study, we tested the selectivity by scanning seven healthy human research volunteers with [(11)c]nnc 112 before and after 2 mg of the antipsychotic drug risperidone, a dose that putatively blocks all 5-ht(2a) receptors with negligible effect on d(1) receptors. |
2007-10-17 |
2023-08-12 |
human |
| Luis R Gardell, Kimberly E Vanover, Linda Pounds, Robert W Johnson, Richard Barido, Gary T Anderson, Isaac Veinbergs, Agnete Dyssegaard, Per Brunmark, Ali Tabatabaei, Robert E Davis, Mark R Brann, Uli Hacksell, Douglas W Bonhau. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. The Journal of pharmacology and experimental therapeutics. vol 322. issue 2. 2007-09-20. PMID:17519387. |
acp-103, a 5-hydroxytryptamine 2a receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. |
2007-09-20 |
2023-08-12 |
Not clear |
| Luis R Gardell, Kimberly E Vanover, Linda Pounds, Robert W Johnson, Richard Barido, Gary T Anderson, Isaac Veinbergs, Agnete Dyssegaard, Per Brunmark, Ali Tabatabaei, Robert E Davis, Mark R Brann, Uli Hacksell, Douglas W Bonhau. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. The Journal of pharmacology and experimental therapeutics. vol 322. issue 2. 2007-09-20. PMID:17519387. |
here we show that acp-103 1) potently inhibited head-twitching produced by the 5-ht(2a/2c) receptor agonist (+/-)-2,5-dimethoxy-4-iodoamphetamine, 2) increased the potency of haloperidol against amphetamine-induced hyperactivity, 3) interacted synergistically with haloperidol or risperidone to suppress hyperactivity induced by the n-methyl-d-aspartate receptor antagonist (5r,10s)-(+)-5-methyl-10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (mk-801), and, by contrast, 4) attenuated haloperido-l- or risperidone-induced prolactinemia. |
2007-09-20 |
2023-08-12 |
Not clear |
| Scott M Myer. The status of pharmacotherapy for autism spectrum disorders. Expert opinion on pharmacotherapy. vol 8. issue 11. 2007-09-17. PMID:17685878. |
empiric evidence of efficacy of risperidone, methylphenidate and some selective serotonin re-uptake inhibitors for maladaptive behaviors commonly associated with autism spectrum disorders has increased substantially in recent years. |
2007-09-17 |
2023-08-12 |
Not clear |
| Yun-Ai Su, Tian-Mei Si, Dong-Feng Zhou, Chun-Mei Guo, Xiao-Dong Wang, Yang Yang, Liang Shu, Jian-Hui Lian. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors. European journal of pharmacology. vol 564. issue 1-3. 2007-08-17. PMID:17395179. |
risperidone attenuates mk-801-induced hyperlocomotion in mice via the blockade of serotonin 5-ht 2a/2c receptors. |
2007-08-17 |
2023-08-12 |
mouse |
| Yun-Ai Su, Tian-Mei Si, Dong-Feng Zhou, Chun-Mei Guo, Xiao-Dong Wang, Yang Yang, Liang Shu, Jian-Hui Lian. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors. European journal of pharmacology. vol 564. issue 1-3. 2007-08-17. PMID:17395179. |
furthermore, (+/-)-1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (doi), a serotonin 5-ht(2a/2c) receptor agonist, at the doses that failed to change spontaneous locomotor activity or hyperlocomotion induced by mk-801, reversed the attenuation by risperidone. |
2007-08-17 |
2023-08-12 |
mouse |
| Yun-Ai Su, Tian-Mei Si, Dong-Feng Zhou, Chun-Mei Guo, Xiao-Dong Wang, Yang Yang, Liang Shu, Jian-Hui Lian. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors. European journal of pharmacology. vol 564. issue 1-3. 2007-08-17. PMID:17395179. |
the serotonin 5-ht(2a/2c) receptor antagonist, ritanserin, enhanced the inhibitory effect of risperidone. |
2007-08-17 |
2023-08-12 |
mouse |
| Yun-Ai Su, Tian-Mei Si, Dong-Feng Zhou, Chun-Mei Guo, Xiao-Dong Wang, Yang Yang, Liang Shu, Jian-Hui Lian. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors. European journal of pharmacology. vol 564. issue 1-3. 2007-08-17. PMID:17395179. |
these findings indicate that risperidone attenuates mk-801-induced hyperlocomotion in mice by blocking serotonin 5-ht(2a/2c) receptors. |
2007-08-17 |
2023-08-12 |
mouse |